Princeton University

Princeton University Center for Human Values

Jason L. Schwartz

Harold T. Shapiro Fellow in Bioethics
University Center for Human Values
        

Jason L. Schwartz 

5 Ivy Lane, Room 105
Princeton, NJ 08544

jlschwar@princeton.edu
609-258-0168 


Education

Ph.D. - University of Pennsylvania   (History and Sociology of Science)

MBE - University of Pennsylvania (Bioethics)

AB - Princeton University (Classics)

 

Selected Publications
Research Interests
Teaching
Home

 

Selected Publications

Schwartz JL. "Rotavirus Vaccines, Intussusception, and Risk-Benefit Assessments." JAMA Pediatrics. 2013; 167(12). (Link)

Schwartz JL. "'Model' patients and the consequences of provider responses to vaccine hesitancy." Human Vaccines. 2013; 9(12). (Link)

Schwartz JL. "Evidence and Ethics in Mandatory Vaccination Policies." American Journal of Bioethics. 2013; 13(9):46-48. (Link)

Schwartz JL. "The First Rotavirus Vaccine and the Politics of Acceptable Risk." The Milbank Quarterly. 2012; 90(2):278-310. (Link)

Caplan AL, Schwartz JL. “Ethics,” in Vaccines. S.A. Plotkin, W. Orenstein, and P. Offit (eds.); 6th Edition, Philadelphia: Elsevier, 2012, 1508-1513. (5th Edition, 2008, pp. 1683-1688). (Link)

Schwartz JL. "New Media, Old Messages: Themes in the History of Vaccine Hesitancy and Refusal." American Medical Association Virtual Mentor. 2012; 14(1):50-55. (Link)

Schwartz JL, Caplan AL. "Vaccination Refusal: Ethics, Individual Rights, and the Common Good." Primary Care. 2011; 38(4):717-728. (Link)

Schwartz JL. “HPV Vaccination’s Second Act: Promotion, Competition, and Compulsion.” American Journal of Public Health. 2010; 100:1841-1844. (Link)

Schwartz JL. “Lessons and Opportunities for Presidential Bioethics Commissions.” The Good Society. 2010; 19(1):10-15. (Link)

Schwartz JL. “Unintended Consequences: The Primacy of Public Trust in Vaccination,” Michigan Law Review First Impressions. 2009; 107:100-105. (Link)

Schwartz JL, Caplan AL, Faden RA, Sugarman J. “Lessons from the Failure of Human Papillomavirus Vaccine State Requirements.” Clinical Pharmacology & Therapeutics. 2007; (82):360-363. (Link)